<DOC>
	<DOCNO>NCT00856596</DOCNO>
	<brief_summary>The topical cream , Sertaconazole ( Ertaczo ) , FDA approve treatment athlete 's foot use twice day dose 4 week . This study want see sertaconazole work equally well day dose 4 week athlete 's foot .</brief_summary>
	<brief_title>Once Day Topical Treatment Athlete 's Foot Fungus Inbetween Toes Males Females</brief_title>
	<detailed_description>The dermatophytes group pathogenic fungi inhabit invade keratinize tissue include hair , skin nail human . Infections cause three genus organism make dermatophytes include : Trichophyton , Microsporum Epidermophyton . Infections due dermatophytes term dermatophytosis tinea . Tinea pedis ( athlete 's foot ) commonly cause Trichophyton rubrum , less commonly Trichophyton mentagrophytes Epidermophyton floccosum . Tinea infection rise variety reason include : age population , increase immunocompromised individual , increase use gym , swimming pool , sport activity , wear occlusive footwear , organism become resistant therapy . Treatment tinea pedis usually involve use topical therapy azoles similar antifungal agent . The efficacy topical agent depend duration therapy , type lesion , mechanism action drug , viscosity , hydrophobicity acidity formulation . Sertaconazole broad spectrum , antifungal agent effective Candida dermatophytes . It also show antibacterial anti-inflammatory activity . Skin absorption study reveal acceptable therapeutic level sertaconazole remain skin 48 hour application . Half life drug clearance skin 60 hour . Skin tolerability phototoxicity study reveal sertaconazole effective safe compare topical antifungal agent . In 2004 sertaconazole nitrate 2 % cream , FDA approve topical treatment interdigital tinea pedis immunocompetent patient 12 year age old , cause Trichophyton rubrum . Trichophyton mentagrophytes Epidermophyton floccosum . The approved dosage twice day total four week affect area . This treatment regimen may prove difficult many patient follow cause low cure rate would expect . It would seem reasonable postulate day application would provide adequate therapeutic level interdigital tinea pedis base several previous finding . Acceptable therapeutic level drug maintain skin 48 hour application half-life drug 60 hour . Patient compliance therefore high mycological cure rate well clinical outcome theoretically occur day dose sertaconazole 2 % . Once day dose prevent early discontinuation well compliance patient tinea pedis .</detailed_description>
	<mesh_term>Tinea</mesh_term>
	<mesh_term>Tinea Pedis</mesh_term>
	<mesh_term>Sertaconazole</mesh_term>
	<criteria>1 . Males females 18 year age . 2 . Women child bear age must negative urine pregnancy test Day 0 ( baseline ) Day 42 ( visit 6 ) discontinuation visit must agree use acceptable method contraception study . 3 . Subjects must clinical evidence interdigital tinea pedis one foot characterize : moderate erythema scale mild pruritis . 4 . The clinical diagnosis must confirm positive KOH preparation , fungal element visible skin scrap interdigital area foot . 5 . Fungal culture obtain baseline visit must positive day 14 subject remain study . 6 . All nonstudy medication specifically exclude protocol may continue . 7 . All chronic disease must stable least one month . 8 . Acute illness must stabilize enrollment . 9 . The subject must able understand require , read sign informed consent , comply requirement study adhere visit schedule . 1 . Under 18 year age . 2 . Pregnant lactating female . 3 . Treatment sertaconazole investigational drug within last 30 day prior study enrollment . 4 . No medication emollient foot powder treatment use study apply treatment area . 5 . The following medication may use study : Oral antifungal 3 month prior enrollment Topical antifungal foot 14 day prior enrollment Systemic antibiotic corticosteroid 30 day prior enrollment Topical corticosteroid 30 day prior enrollment Use radiation therapy and/or antineoplastic agent within1 year enrollment 6 . Widespread dermatophytosis : moccasin tinea pedis , onychomycosis , oral , vaginal chronic mucocutaneous candidiasis , bacterial skin infection . 7 . Subject know suspect immunocompromised . 8 . Known sensitivity component test medication hypersensitivity imidazole . 9 . Any disease condition may compromise evaluation therapeutic response tinea pedis treatment . 10 . History drug alcohol dependency last 6 month . 11 . History atopic contact dermatitis foot . 12 . Unstable diabetes mellitus . 13 . Subjects participate previous clinical trial sertaconazole . 14 . Subjects sign inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Tinea pedis</keyword>
	<keyword>Fungus</keyword>
	<keyword>Pruritus</keyword>
	<keyword>Dermatophyte</keyword>
	<keyword>Athlete 's foot</keyword>
	<keyword>Dermatomycosis</keyword>
	<keyword>Skin manifestation</keyword>
	<keyword>Infectious skin disease</keyword>
	<keyword>Foot disease</keyword>
</DOC>